Case 1 Male patient died while receiving semaglutide report invalidated because call-center contractors claimed patient identifier was missing (FDA found it in source documents) Case 2 Consumer taking liraglutide suffered a disabling stroke report cancelled because the consumer said it was unrelated to the drug Case 3 Patient taking semaglutide became depressed and committed suicide no follow-up attempts documented, still not submitted to FDA as of March 2026 Case 4 Consumer reported suicidal ideation on semaglutide in December 2024 not reviewed until February 2025, only after FDA inspectors flagged it Case 5 FDA found Novo Nordisk's written procedures allowed adverse events to be rejected based on causality assessments contradicting federal reporting requirements A Second Front: Vision Loss Claims Beyond the GI injury cases, a second GLP-1 MDL was created in December 2025 for vision loss claims
$1,300+ retail Zepbound: $349 cash-pay (via manufacturer program)
Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al
Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
This differs from the approved low-dose titration schedules (such as starting semaglutide at 0.25mg) that manufacturers recommend to improve tolerability
/assets/images/provider/photos/2775905.jpeg)
